ACEPODIA, INC.
Update：2025/12/24
Industries
Main Industry
Biotechnology
Main Product/Service
Acepodia’s core offering is allogeneic cell‑therapy for cancer — using targeted design and cell‑engineering technologies to develop safe and effective therapeutic cell drugs, aiming to provide patients with a next‑generation, broadly applicable cancer tre
Founded Year
2023
Unified Business No.
82983710
Status
Active
Number of Employees
60
Total Paid-in
Capital
0 (NT$)
Exit Status
Emerging Stock Exchange(2023)
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, Ministry of Economic Affairs.
Exclusive content for members
Members-only content. Please log in to access.
Introduction
Acepodia Inc., a member (No. 64) of the Taiwan Research‑based Biopharmaceutical Manufacturers Association (TRPMA), is a biotech startup focused on developing novel allogeneic cell therapies for cancer, aiming to advance new possibilities in oncology treat
